Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA issues another response letter for dry eye NDA ➤ FDA denies approval for LHON NDA ➤ Commercial launch of epithelium-on crosslinking in the U.S. ➤ Company news ➤ ASCRS news and events
➤ FDA approves new EDOF with limited dysphotopsias ➤ Phase 1/2 12-month data for IOL-based drug delivery system ➤ Topline results from Phase 2a wet AMD study ➤ FDA grants Breakthrough Device Designation to brain implant technology ➤ FDA allows Phase 1/2 trial to begin for investigational cell therapy for familial drusen ➤ ASCRS news and events
➤ First patients dosed in Phase 3 program evaluating sustained drug delivery for DME ➤ FDA accepts supplemental NDA for presbyopia treatment ➤ FDA grants IND to ocular inflammation, pain treatment for potential expanded indication ➤ Enrollment complete in Phase 3 trial evaluating retinitis pigmentosa therapy ➤ ASCRS news and events
➤ First patient treated with novel crosslinking approach for refractive error ➤ Multisociety working group established to set guidelines for modern IOL classification ➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial ➤ ASCRS news and events
➤ Positive results in Phase 3 superiority trial for wet AMD treatment ➤ Dosing begins for first-in-human myopia prevention drop ➤ Pre-NDA meeting with FDA for IOP-lowering drop ➤ Company news ➤ ASCRS news and events
➤ Enrollment complete in Phase 3 trial for wet AMD ➤ Dosing complete in Phase 1/2 trial for retinitis pigmentosa treatment ➤ First patient dosed in gene therapy study for optic nerve disorder ➤ Company news
➤ New drop for temporary presbyopia relief approved ➤ First-in-human results for accommodating IOL ➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy ➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response ➤ First patient receives investigational surgical system for glaucoma ➤ Clinical program for RP gene therapy begins ➤ FDA approves IND for steroid-free, topical anti-inflammatory ➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Enrollment complete in first-in-human trial evaluating treatment for patients with Usher syndrome ➤ First patients randomized in drug-eluting IOL trial ➤ Preliminary data from Phase 2 gene modifier study for geographic atrophy ➤ ASCRS news and events
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.